Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completed

Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

NCT07418138
completed

Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation

NCT05685888
completed

Effects of Antiviral Therapy on Patients With HBV-related HCC

NCT05406089

Clinical Trials (3)

Showing 3 of 3 trials
NCT07418138

Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

Completed
NCT05685888

Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation

Completed
NCT05406089

Effects of Antiviral Therapy on Patients With HBV-related HCC

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3